Watch: Looking to RNA-Modifying Proteins to Tackle Cancer

Lexington, MA-based Accent Therapeutics has a new idea to fight cancer. The idea is to develop drugs that target what are called RNA-modifying proteins (RMPs). RMPs modify RNA after they are produced by the DNA but before the RNA is translated into proteins. The activities of some RMPs have been linked to the development of certain cancers.

Accent believes inhibiting these proteins could be a more precise way of attacking cancer. Only two other companies are attempting to do something similar: U.K.-based Storm Therapeutics and NYC-based Gotham Therapeutics. Accent believes this approach is a fertile field for anticancer drug development.

Follow us on social media for the latest updates in B2B!

Latest

BioTech Startups Want to Revive Failed Medicines to Create New Lifesaving Treatments
Behind the Clinical Trials for Non-Alcohol Fatty Liver Disease that Can Benefit 30% of Americans
July 1, 2022
  The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She Read more
FABTECH Show Kickoff and Overview of Solutions Distributed by DeGeest
June 30, 2022
This is another episode of Manufacturing A Stronger Standard live from FABTECH 2021. Host and President of LestaUSA and DeGeest Corp., Derek DeGeest, talked with Brad Ruppert, Engineering Manager, and Read more
Improving Quality and Bottomline for Finishing Operations
June 30, 2022
This is another episode of Manufacturing A Stronger Standard from FABTECH 2021. Host and President of Lesta USA and Degeest Corp., Derek Degeest, talked with Bill Robinson, President and Kris Bonnegent, Regional Read more